This case report discusses bilateral vision loss 2 weeks after second bilateral intravitreal injection of the anti–vascular endothelial growth factor (VEGF) brolucizumab for diabetic macular edema in a woman in her 60s.
Ramtohul et al. (Thu,) studied this question.